Fundraising FoxIaso Ventures — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Certara provides biosimulation software, modeling, and regulatory services that support drug discovery and development across discovery, preclinical, clinical, regulatory, and market access phases.
AI & Machine LearningBiotechHealthtechSaaSRadnor, US
Daniel Corcoran(SVP and General Counsel)inWilliam Feehery(CEO and Director)inJieun W. Choe(Chief Strategy & Marketing Officer)inRichard M. Traynor(Senior Vice President and General Counsel)inCraig R. Rayner(President, Integrated Drug Development)Justin Edge(President, Regulatory and Access)in
Board seatJohn Reynders· per SEC Form D · filed Apr 2026
Co-investorsArsenal
Aerska develops RNA interference (RNAi) medicines designed for targeted delivery across the blood-brain barrier to treat, delay, and prevent central nervous system and neurological diseases.
BiotechDeep TechHealthtechMedical Devices
Stuart Milstein(Co-Founder)inJack O’Meara(Cofounder)in
Co-investorsage1BackedBlueYard CapitalEntrepreneur FirstGlobal Health Investment CorporationLingotto+6 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.